- In April 2023, Tilray Brands, Inc., a leading global cannabis-lifestyle and consumer packaged goods company, expanded its European footprint by launching medical cannabis products in the Czech Republic. This strategic move is part of Tilray’s broader initiative to strengthen its presence across Europe by leveraging local partnerships and meeting the growing demand for pharmaceutical-grade cannabis, especially in pain and neurology management
- In March 2023, Aurora Cannabis Inc. announced the successful completion of its first shipment of medical cannabis to Australia under its supply agreement with MedReleaf Australia. This milestone signifies Aurora’s growing influence in the Asia-Pacific region and reinforces its role as a key supplier of high-quality cannabis to emerging regulated markets, supporting patients with chronic pain and other medical conditions
- In March 2023, Curaleaf Holdings, Inc. launched a new line of precision-dosed THC and CBD capsules under its medical division in the U.S. market. These products are formulated to provide patients with consistent and controlled dosing for managing conditions such as anxiety, arthritis, and insomnia. This development emphasizes Curaleaf’s commitment to clinical precision and expanding access to alternative therapies
- In February 2023, Canopy Growth Corporation announced a strategic shift to focus more heavily on its medical marijuana operations, including the expansion of its German subsidiary, C³ Cannabinoid Compound Company. This move aligns with Germany’s progressive regulatory environment and growing patient base, supporting Canopy’s goal of establishing leadership in the European medical cannabis market
- In January 2023, Jazz Pharmaceuticals plc, the parent company of GW Pharmaceuticals, initiated a new phase of research into expanded indications for Epidiolex, its FDA-approved CBD-based treatment for severe forms of epilepsy. This advancement highlights continued efforts to broaden the therapeutic scope of medical cannabis and reinforce its clinical credibility across new neurological applications
